Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
50.41
+1.10 (2.23%)
Aug 10, 2026, 10:45 AM EDT - Market open
Boston Scientific Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 755 | 2,892 | 1,846 | 1,592 | 698 | 1,041 |
Depreciation & Amortization | 1,413 | 1,368 | 1,269 | 1,196 | 1,136 | 1,093 |
Stock-Based Compensation | 320 | 299 | 266 | 233 | 220 | 194 |
Other Adjustments | -376 | 221 | 515 | 254 | 478 | -106 |
Change in Receivables | -293 | -269 | -351 | -238 | -220 | -279 |
Changes in Inventories | -454 | -188 | -228 | -660 | -321 | -346 |
Changes in Accounts Payable | 172 | 296 | 243 | 118 | -255 | 408 |
Changes in Other Operating Activities | -67 | -85 | -126 | 10 | -209 | -134 |
Operating Cash Flow | 4,529 | 4,534 | 3,435 | 2,503 | 1,526 | 1,870 |
Operating Cash Flow Growth | 5.69% | 31.99% | 37.23% | 64.02% | -18.40% | 24.01% |
Capital Expenditures | -904 | -876 | -790 | -711 | -588 | -554 |
Sale of Property, Plant & Equipment | - | - | - | - | 12 | 14 |
Purchases of Investments | - | -254 | -280 | -89 | -24 | - |
Proceeds from Sale of Investments | - | - | - | - | - | 279 |
Cash Acquisitions | -1,063 | -1,593 | -4,640 | -1,811 | -1,542 | -2,258 |
Proceeds from Business Divestments | - | - | - | - | 5 | 826 |
Other Investing Activities | 47 | 84 | 23 | 37 | 126 | 97 |
Investing Cash Flow | -3,561 | -2,640 | -5,687 | -2,574 | -2,011 | -1,597 |
Short-Term Debt Repaid | -284 | - | -25 | -4 | -250 | - |
Net Short-Term Debt Issued (Repaid) | -284 | - | -25 | -4 | -250 | - |
Long-Term Debt Issued | - | 1,558 | 2,145 | - | 3,270 | - |
Long-Term Debt Repaid | - | - | - | - | -3,184 | - |
Net Long-Term Debt Issued (Repaid) | - | 1,558 | 2,145 | - | 86 | - |
Issuance of Common Stock | 201 | 282 | 230 | 182 | 136 | 110 |
Repurchase of Common Stock | -96 | -131 | -87 | -56 | -53 | -50 |
Net Common Stock Issued (Repurchased) | 105 | 151 | 143 | 126 | 83 | 60 |
Preferred Share Dividends Paid | - | - | - | - | -55 | -55 |
Other Financing Activities | 7 | -1,908 | -328 | -303 | -411 | -100 |
Financing Cash Flow | -958 | -395 | 1,814 | 5 | -548 | -95 |
Foreign Exchange Rate Adjustments | 2 | 42 | -11 | -4 | -9 | -6 |
Net Cash Flow | 12 | 1,541 | -450 | -70 | -1,042 | 173 |
Free Cash Flow | 3,625 | 3,658 | 2,645 | 1,792 | 938 | 1,316 |
Free Cash Flow Growth | 4.02% | 38.30% | 47.60% | 91.05% | -28.72% | 16.25% |
FCF Margin | 17.27% | 18.22% | 15.79% | 12.58% | 7.40% | 11.07% |
Free Cash Flow Per Share | 2.43 | 2.45 | 1.78 | 1.22 | 0.65 | 0.91 |
Levered Free Cash Flow | 3,551 | 4,971 | 4,341 | 1,519 | 241 | 1,452 |
Unlevered Free Cash Flow | 4,106 | 3,602 | 2,474 | 1,832 | 771.77 | 1,626 |